Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 8/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965289 | 1.00 | HTR2A (0.42) | HTR2APPARAPPARGSOAT1USP2 | |
| SCHEMBL3964918 | 1.00 | HTR2A (0.42) | HTR2APPARAPPARGSOAT1USP2 | |
| SCHEMBL3962800 | 0.92 | PPARA (0.47) | HTR2APPARAPPARGPPARD | |
| SCHEMBL4073462 | 0.92 | PPARA (0.47) | HTR2APPARAPPARGPPARD | |
| SCHEMBL3963764 | 0.92 | PPARA (0.47) | HTR2APPARAPPARGPPARD | |
| SCHEMBL3965062 | 0.92 | PPARA (0.47) | HTR2APPARAPPARGPPARD | |
| SCHEMBL3968805 | 0.89 | PPARA (0.48) | HTR2APPARAPPARGUSP2HSD17B10 | |
| SCHEMBL3956930 | 0.87 | MAPT (0.41) | HTR2APPARAPPARGPPARDMME | |
| SCHEMBL3960456 | 0.87 | FFAR1 (0.43) | HTR2APPARAPPARGUSP2HSD17B10 | |
| SCHEMBL3960794 | 0.83 | TRPM8 (0.52) | PPARAPPARGLTB4R2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | HTR2A 4493/4885PPARA 346/4885PPARG 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.